TrialInvestigational new drugs2023

A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.

Mingzhen Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.